Track topics on Twitter Track topics that are important to you
South San Francisco-based Cortexyme closed on a $76 million Series B financing round.
Cortexyme Inc. (neurodegenerative disease therapeutics with a focus on Alzheimer's) raised $76mm in a Series B round from new investors Sequoia Capital, Vulcan Capital, Verily Life Sciences, EPIQ Capi...
Cortexyme has also finished enrolling healthy volunteers in the
Preclinical and clinical data supporting bacterial pathogenesis of Alzheimer’s brought Sequoia onto Cortexyme’s $76 million series B.
– Cortexyme has successfully completed key components of its phase 1 clinical development program for lead compound COR388 – Cortexyme, Inc., a clinical-stage pharmaceutic...
-- Cortexyme’s lead compound represents a promising new approach to addressing Alzheimer’s -- -- First two studies in the phase 1 trial program will enroll a total ...
Based in South San Francisco, California, Cortexyme is a privately held, clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimerâs and ...
We have published hundreds of Cortexyme, Inc. news stories on BioPortfolio along with dozens of Cortexyme, Inc. Clinical Trials and PubMed Articles about Cortexyme, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cortexyme, Inc. Companies in our database. You can also find out about relevant Cortexyme, Inc. Drugs and Medications on this site too.
Psychiatry is the study of mental disorders and their diagnosis, management and prevention. Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...